Summary
The remission rates after endocrine and cytostatic treatment were determined in 192 female patients with advanced breast cancer depending on the estrogen, progesterone, and androgen receptor content and on the diseasedominant site.
Of 60 women with tumors containing estradiol receptors 39 responded to endocrine treatment. This was only true in two of 31 women without estradiol receptors.
Tumors which contained binding sites for both estradiol and progesterone had a higher remission rate after endocrine therapy than those with estradiol receptors only.
Remission rates after polychemotherapy were also higher in tumors with binding sites for estradiol as well as for progesterone.
The localisation of metastases seems to be of lesser importance for the remission rate than the receptor content. Liver metastases are an exception. Here, no remissions could be observed with endocrine treatment even if ER and PR were present.
The median remission rate was 9 months for hormonally treated patients and 10 months for those undergoing chemotherapy.
The median survival time after chemotherapy is 18 months higher for responders than for non-responders. This difference is 15 months with endocrine treatment.
Two years after the start of endocrine treatment 60% of the responders but only 20% of the non-responders were still alive.
Based on our results together with histomorphological studies and the evaluation of recurrence and survival it can be assumed that carcinomas, which by nature follow a more benign course, do contain estradiol receptors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bloom ND, Tobin EH, Schreibman B, Degenshein GA (1980) The role of progesterone receptors in the management of advanced breast cancer. Cancer 45:2992–2997
Engelsman E, Persijin JP, Korsten CB (1978) Experience with estrogen and androgen receptors in breast cancer: Correlation with clinical data. In: Mayer M, Saez S, Stoll BA (eds) Hormone deprivation in breast cancer. Reviews on endocrine related cancer [Suppl] pp 22–36
Hayward JL, Carbone PP, Heuson JC, Kumaoka, Segaloff A, Rubens RD (1977) Assessment of response to therapy in advanced breast cancer. Cancer 39:1289–1293
Hilf R, Feldstein ML, Gibson SL, Savlov ED (1980) The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer. Cancer 45:1993–2000
Jensen EV, Smith S, DeSombre ER (1976) Hormone dependency in breast cancer. J Ster Biochem 7:911–917
Kaplan EL, Meier P (1958) Non-parametric estimations from incomplete observations. J Am Stat Assoc 53:457–482
Kiang DT, Frenning DH, Goldman AI, Ascensao VF, Kennedy BJ (1978) Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med 299:1330–1334
Lippman ME, Allegra JC, Thompson EB, Simon R, Barlock A, Green L, Huff KK, My T Do H, Aitken SC, Warren R (1978) The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 298:1223
Maillot K von, Hermanek P, Gentsch HH (1979a) Steroid receptors in tumors of tissues generally considered to be hormone-independent. J Cancer Res Clin Oncol 93:77–84
Maillot K von, Egger H, Gentsch HH (1979b) Prognostic significance of steroid receptors in breast cancer. Cancer Treat Rep 63:1190
Matsumoto K, Ochi H, Nomura Y, Takatani O, Izuo M, Okamoto R, Sugano H (1978) Progesterone and estrogen receptors in Japanese breast cancer. In: McGuire WL (ed) Hormones, receptors and breast cancer. Raven Press, New York, pp 43–58
May-Levin R, Delarue JC, Bohuon C, Contesso G (1978) Estrogen and progesterone cytosol receptors in human malignant and benign breast lesions. In: Mayer M, Saez S, Stoll B (eds) Hormone deprivation in breast cancer. Rev Endocrine-related Cancer, pp 68–75
McGuire WL, Carbone PP, Sears ME, Escher GC (1974) Estrogen receptors in human breast cancer. An overview. In: McGuire WL, Carbone PP, Vollmer EP (eds) Estrogen receptors in human breast cancer. Raven Press, New York, pp 1–7
McGuire WL, Horwitz KB, Pearson OH, Segaloff A (1977) A current status of estrogen and progesterone receptors in breast cancer. Cancer 39:2934–2947
McGuire WL, Horwitz KB (1978) Progesterone receptors in breast cancer. In: McGuire WL (ed) Hormones, receptors, and breast cancer. Raven Press, New York, pp 31–42
Samal B, Singhakowinta A, Brooks SC, Vaitkevitius VK (1978) Estrogen receptors and response of breast cancer to chemotherapy. To the Editor. N Engl J Med 299:604
Scatchard G (1949) The attractions of proteins for small molecules and ions. Ann NY Acad Sci 51:660
Skinner LG, Barnes DM, Ribeiro GG (1979) Triple hormone receptor assay. A more accurate predictive tool in breast cancer prognosis. Cancer Treat Rep 63:1186
Webster DJT, Bronn DG, Minton JP (1978) Estrogen receptors and response of breast cancer to chemotherapy. To the Editor. N Engl J Med 299:604
Young PCM, Einhorn LH, Ehrlich CE, Cleary RE, Rohn RJ (1978) Progesterone receptor (PGR) as a marker of hormone-responsive human breast tumor. Proc Am Assoc Cancer Res 19:204
Author information
Authors and Affiliations
Additional information
Supported by a grant of the Deutsche Forschungsgemeinschaft, SFB 118, “Grundlagen der Früherkennung und der Verlaufsbeobachtung des Krebses”
Rights and permissions
About this article
Cite this article
von Maillot, K., Gentsch, H.H. & Gunselmann, W. Steroid receptors and response to endocrine treatment and chemotherapy of advanced breast cancer. J Cancer Res Clin Oncol 98, 301–313 (1980). https://doi.org/10.1007/BF00410792
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00410792